drugset

Drugs / CV0701

Follow last change Aug 2024 re-read 3 minutes ago

CV0701

Developed for: COVID-19
Investigated by: CureVac · GlaxoSmithKline

Trials 1

today NCT05960097 · Ph 2

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05960097	Aug 2023 → Aug 2024	COVID-19	GlaxoSmithKline	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2024-01-05	CureVac	Results CureVac veröffentlicht positive Interim-Phase 2-Daten des COVID-19-Impfstoff-Entwicklungsprogramms in Zusammenarbeit mit GSK, die starke Validierung der firmeneigenen Technologie-Plattform belegen curevac.com ↗

All press releases naming this drug 1 release

Date	Issuer	Release
2024-01-05	CureVac	CureVac veröffentlicht positive Interim-Phase 2-Daten des COVID-19-Impfstoff-Entwicklungsprogramms in Zusammenarbeit mit GSK, die starke Validierung der firmeneigenen Technologie-Plattform belegen curevac.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	CV0701	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05960097 ↗
Route	Intramuscular	“Study vaccine was administered as a single intramuscular injection.” NCT05960097 ↗